Targeted Oncology14h
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.
Fierce Biotech23h
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
The American Journal of Managed Care16h
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
BioSpace23h
BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients
BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.
eLife19h
Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines
Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
MPR20h
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.